July 09, 2025 a 06:00 pm
PODD: Fundamental Ratio Analysis - Insulet Corporation
Insulet Corporation, known for its innovative insulin delivery systems, operates in a growing market with a solid business model. With its strong presence in North America and expanding influence in international markets, the company maintains a competitive edge. Strategic partnerships and technological advancements remain critical for its future growth.
Fundamental Rating
Insulet Corporation has maintained a moderate fundamental score, indicating an average performance compared to industry standards.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 1 | |
| Return On Equity | 5 | |
| Return On Assets | 5 | |
| Debt To Equity | 3 | |
| Price To Earnings | 1 | |
| Price To Book | 1 |
Historical Rating
The historical scores show an improvement in the overall rating, mirroring certain financial adjustments and market conditions.
| Date | Overall | DCF | ROE | ROA | DTE | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-09 | 3 | 1 | 5 | 5 | 3 | 1 | 1 |
| Previous | 0 | 1 | 5 | 5 | 3 | 1 | 1 |
Analyst Estimates
Analysts show confidence in Insulet's performance, indicating a stable forecast across high, low, and median price targets.
| High | Low | Median | Consensus |
|---|---|---|---|
| 322 | 322 | 322 | 322 |
Analyst Sentiment
The analyst sentiment reflects a positive outlook with a majority recommending a 'Buy'.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 28 | |
| Hold | 13 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Insulet Corporation showcases a balanced mix of innovation and market presence, with analysts largely favoring a buy recommendation. The stability in price targets reflects market confidence, alongside incremental improvements in fundamental scores. However, challenges such as market competition and regulatory shifts could pose risks. Continued innovation and strategic partnerships are likely to enhance future growth prospects.